Company intelligence / Profile preview

Audiotek

Amsterdam, North Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

Audion Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of hearing loss. The company's primary focus is on sensorineural hearing loss, which is caused by the loss of hair cells in the inner ear. Audion's lead program utilizes a small molecule gamma-secretase inhibitor designed to trigger the regeneration of these hair cells by modulating the Notch signaling pathway. By targeting the underlying biological cause of hearing impairment, the company aims to provide a disease-modifying alternative to traditional hearing aids and cochlear implants.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eli Lilly

Beyond the preview

Go deeper on Audiotek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Audiotek.

Explore the full profile